Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia

详细信息    查看全文

• 作者：Frances Wadelin (1)
  Joel Fulton (1)
  Paul A McEwan (2)
  Keith A Spriggs (3)
  Jonas Emsley (2)
  David M Heery (1)
  
• 刊名：Molecular Cancer
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：9
• 期：1
• 全文大小：1105KB
• 参考文献：1. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. / Immunity 1997, 6:199鈥?08. CrossRef
  2. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR, Allen RE, Singer MI, / et al.: The gene expression signatures of melanoma progression. / Proc Natl Acad Sci USA 2005, 102:6092鈥?097. CrossRef
  3. Williams JM, Chen GC, Zhu L, Rest RF: Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth. / Mol Microbiol 1998, 27:171鈥?86. CrossRef
  4. Nakamura Y, Tanaka F, Nagahara H, Ieta K, Haraguchi N, Mimori K, Sasaki A, Inoue H, Yanaga K, Mori M: Opa interacting protein 5 (OIP5) is a novel cancer-testis specific gene in gastric cancer. / Ann Surg Oncol 2007, 14:885鈥?92. CrossRef
  5. Kawasaki K, Minoshima S, Nakato E, Shibuya K, Shintani A, Schmeits JL, Wang J, Shimizu N: One-megabase sequence analysis of the human immunoglobulin lambda gene locus. / Genome Res 1997, 7:250鈥?61. CrossRef
  6. Croce CM, Huebner K, Isobe M, Fainstain E, Lifshitz B, Shtivelman E, Canaani E: Mapping of four distinct BCR-related loci to chromosome region 22q11: order of BCR loci relative to chronic myelogenous leukemia and acute lymphoblastic leukemia breakpoints. / Proc Natl Acad Sci USA 1987, 84:7174鈥?178. CrossRef
  7. Schenk T, Stengel S, Goellner S, Steinbach D, Saluz HP: Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. / Genes Chromosomes Cancer 2007, 46:796鈥?04. CrossRef
  8. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R: The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. / Cell 2005, 122:835鈥?47. CrossRef
  9. Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, Heslop HE, Rooney CM, Pane F, Savoldo B: Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. / Blood 2008, 112:1876鈥?885. CrossRef
  10. Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, Horvath G: Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. / Int J Cancer 2008, 123:2130鈥?137. CrossRef
  11. Proto-Siqueira R, Figueiredo-Pontes LL, Panepucci RA, Garcia AB, Rizzatti EG, Nascimento FM, Ishikawa HC, Larson RE, Falcao RP, Simpson AJ, / et al.: PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. / Leuk Res 2006, 30:1333鈥?339. CrossRef
  12. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, / et al.: Gene expression changes associated with progression and response in chronic myeloid leukemia. / Proc Natl Acad Sci USA 2006, 103:2794鈥?799. CrossRef
  13. van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG: PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. / Br J Haematol 1998, 102:1376鈥?379. CrossRef
  14. Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B: Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. / Cancer Genet Cytogenet 2002, 133:118鈥?23. CrossRef
  15. Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley T, Yang T, Epping MT, Shou Y, Pogosova-Agadjanyan E, / et al.: The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. / Blood 2009, 114:3299鈥?308. CrossRef
  16. Santamaria C, Chillon MC, Garcia-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queizan JA, Penarrubia MJ, / et al.: The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. / Haematologica 2008, 93:1797鈥?805. CrossRef
  17. Qin Y, Zhu H, Jiang B, Li J, Lu X, Li L, Ruan G, Liu Y, Chen S, Huang X: Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. / Leuk Res 2009, 33:384鈥?90. CrossRef
  18. Matsushita M, Ikeda H, Kizaki M, Okamoto S, Ogasawara M, Ikeda Y, Kawakami Y: Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. / Br J Haematol 2001, 112:916鈥?26. CrossRef
  19. Steinbach D, Viehmann S, Zintl F, Gruhn B: PRAME gene expression in childhood acute lymphoblastic leukemia. / Cancer Genet Cytogenet 2002, 138:89鈥?1. CrossRef
  20. Proto-Siqueira R, Falcao RP, de Souza CA, Ismael SJ, Zago MA: The expression of PRAME in chronic lymphoproliferative disorders. / Leuk Res 2003, 27:393鈥?96. CrossRef
  21. Pellat-Deceunynck C, Mellerin MP, Labarriere N, Jego G, Moreau-Aubry A, Harousseau JL, Jotereau F, Bataille R: The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. / Eur J Immunol 2000, 30:803鈥?09. CrossRef
  22. Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, Chauffaille ML, Andriolo A, Caballero OL, Zago MA, Colleoni GW: Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. / Cancer Immun 2008, 8:2.
  23. Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O'Driscoll L: Prevalence and prognostic and predictive relevance of PRAME in breast cancer. / Breast Cancer Res Treat 2008, 109:359鈥?65. CrossRef
  24. Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R: PRAME expression and clinical outcome of breast cancer. / Br J Cancer 2008, 99:398鈥?03. CrossRef
  25. Sun Y, Urquidi V, Goodison S: Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach. / Breast Cancer Res Treat 2009,119(3):593鈥?. CrossRef
  26. Figueiredo DL, Mamede RC, Proto-Siqueira R, Neder L, Silva WA Jr, Zago MA: Expression of cancer testis antigens in head and neck squamous cell carcinomas. / Head Neck 2006, 28:614鈥?19. CrossRef
  27. Boon K, Edwards JB, Siu IM, Olschner D, Eberhart CG, Marra MA, Strausberg RL, Riggins GJ: Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. / Oncogene 2003, 22:7687鈥?694. CrossRef
  28. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M: The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. / Clin Cancer Res 2004, 10:4307鈥?313. CrossRef
  29. Watari K, Tojo A, Nagamura-Inoue T, Nagamura F, Takeshita A, Fukushima T, Motoji T, Tani K, Asano S: Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. / FEBS Lett 2000, 466:367鈥?71. CrossRef
  30. Passeron T, Valencia JC, Namiki T, Vieira WD, Passeron H, Miyamura Y, Hearing VJ: Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. / J Clin Invest 2009, 119:954鈥?63.
  31. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. / Proc Natl Acad Sci USA 1996, 93:7149鈥?153. CrossRef
  32. Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M: Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. / Cancer Res 2004, 64:9167鈥?171. CrossRef
  33. Ortmann CA, Eisele L, Nuckel H, Klein-Hitpass L, Fuhrer A, Duhrsen U, Zeschnigk M: Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. / Ann Hematol 2008, 87:809鈥?18. CrossRef
  34. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Jose-Eneriz ES, Garate L, Cordeu L, Cervantes F, Prosper F, / et al.: Epigenetic regulation of PRAME gene in chronic myeloid leukemia. / Leuk Res 2007, 31:1521鈥?528. CrossRef
  35. Luetkens T, Schafhausen P, Uhlich F, Stasche T, Akbulak R, Bartels BM, Hildebrandt Y, Gontarewicz A, Kobold S, Meyer S, / et al.: Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. / Leuk Res 2010, in press.
  36. Gunn SR, Bolla AR, Barron LL, Gorre ME, Mohammed MS, Bahler DW, Mellink CH, van Oers MH, Keating MJ, Ferrajoli A, / et al.: Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. / Leuk Res 2009, 33:1276鈥?281. CrossRef
  37. Bea S, Salaverria I, Armengol L, Pinyol M, Fernandez V, Hartmann EM, Jares P, Amador V, Hernandez L, Navarro A, / et al.: Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. / Blood 2009, 113:3059鈥?069. CrossRef
  38. Birtle Z, Goodstadt L, Ponting C: Duplication and positive selection among hominin-specific PRAME genes. / BMC Genomics 2005, 6:120. CrossRef
  39. Tian X, Pascal G, Monget P: Evolution and functional divergence of NLRP genes in mammalian reproductive systems. / BMC Evol Biol 2009, 9:202. CrossRef
  40. Evsikov AV, Graber JH, Brockman JM, Hampl A, Holbrook AE, Singh P, Eppig JJ, Solter D, Knowles BB: Cracking the egg: molecular dynamics and evolutionary aspects of the transition from the fully grown oocyte to embryo. / Genes Dev 2006, 20:2713鈥?727. CrossRef
  41. Dade S, Callebaut I, Mermillod P, Monget P: Identification of a new expanding family of genes characterized by atypical LRR domains. Localization of a cluster preferentially expressed in oocyte. / FEBS Lett 2003, 555:533鈥?38. CrossRef
  42. Kajava AV: Structural diversity of leucine-rich repeat proteins. / J Mol Biol 1998, 277:519鈥?27. CrossRef
  43. McEwan PA, Scott PG, Bishop PN, Bella J: Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. / J Struct Biol 2006, 155:294鈥?05. CrossRef
  44. Kobe B, Deisenhofer J: Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. / Nature 1993, 366:751鈥?56. CrossRef
  45. Kelley LA, Sternberg MJ: Protein structure prediction on the Web: a case study using the Phyre server. / Nat Protoc 2009, 4:363鈥?71. CrossRef
  46. Lee MS, Kim YJ: Signaling pathways downstream of pattern-recognition receptors and their cross talk. / Annu Rev Biochem 2007, 76:447鈥?80. CrossRef
  47. Tajeddine N, Gala JL, Louis M, Van Schoor M, Tombal B, Gailly P: Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. / Cancer Res 2005, 65:7348鈥?355. CrossRef
  48. Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, Brown R, Bernards R: A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. / Proc Natl Acad Sci USA 2007, 104:17777鈥?7782. CrossRef
  49. Heery DM, Kalkhoven E, Hoare S, Parker MG: A signature motif in transcriptional co-activators mediates binding to nuclear receptors. / Nature 1997, 387:733鈥?36. CrossRef
  50. Lehner B, Semple JI, Brown SE, Counsell D, Campbell RD, Sanderson CM: Analysis of a high-throughput yeast two-hybrid system and its use to predict the function of intracellular proteins encoded within the human MHC class III region. / Genomics 2004, 83:153鈥?67. CrossRef
  51. Markson G, Kiel C, Hyde R, Brown S, Charalabous P, Bremm A, Semple J, Woodsmith J, Duley S, Salehi-Ashtiani K, / et al.: Analysis of the human E2 ubiquitin conjugating enzyme protein interaction network. / Genome Res 2009, 19:1905鈥?911. CrossRef
  52. Steinbach D, Pfaffendorf N, Wittig S, Gruhn B: PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia. / Cancer Genet Cytogenet 2007, 177:51鈥?4. CrossRef
  53. Goellner S, Steinbach D, Schenk T, Gruhn B, Zintl F, Ramsay E, Saluz HP: Childhood acute myelogenous leukaemia: association between PRAME, apoptosis-and MDR-related gene expression. / Eur J Cancer 2006, 42:2807鈥?814. CrossRef
  54. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, Bullinger L: Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. / Blood 2006, 108:4109鈥?117. CrossRef
  55. Tajeddine N, Millard I, Gailly P, Gala JL: Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. / Clin Chem Lab Med 2006, 44:548鈥?55. CrossRef
  56. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, / et al.: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. / Blood 2000, 96:4075鈥?083.
  57. Santamaria CM, Chillon MC, Garcia-Sanz R, Perez C, Caballero MD, Ramos F, Garcia de Coca A, Alonso JM, Giraldo P, Bernal T, / et al.: Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia (CN-AML). / Blood 2009, 114:148鈥?52. CrossRef
  58. Kawano R, Karube K, Kikuchi M, Takeshita M, Tamura K, Uike N, Eto T, Ohshima K, Suzumiya J: Oncogene associated cDNA microarray analysis shows PRAME gene expression is a marker for response to anthracycline containing chemotherapy in patients with diffuse large B-cell lymphoma. / J Clin Exp Hematop 2009, 49:1鈥?. CrossRef
  59. Staege MS, Banning-Eichenseer U, Weissflog G, Volkmer I, Burdach S, Richter G, Mauz-Korholz C, Foll J, Korholz D: Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs. / Exp Hematol 2008, 36:886鈥?96. CrossRef
  60. Steinbach D, Schramm A, Eggert A, Onda M, Dawczynski K, Rump A, Pastan I, Wittig S, Pfaffendorf N, Voigt A, / et al.: Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. / Clin Cancer Res 2006, 12:2434鈥?441. CrossRef
  61. Paydas S, Tanriverdi K, Yavuz S, Seydaoglu G: PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. / Leuk Res 2007, 31:365鈥?69. CrossRef
  62. Greiner J, Dohner H, Schmitt M: Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens. / Haematologica 2006, 91:1653鈥?661.
  63. Griffioen M, Kessler JH, Borghi M, van Soest RA, van der Minne CE, Nouta J, van der Burg SH, Medema JP, Schrier PI, Falkenburg JH, / et al.: Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. / Clin Cancer Res 2006, 12:3130鈥?136. CrossRef
  64. Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S, Savani BN, Keyvanfar K, Li Y, Kurlander R, Barrett AJ: Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. / Blood 2009, 113:2245鈥?255. CrossRef
  65. Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, Dohner H, Schmitt M: mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. / Int J Cancer 2004, 108:704鈥?11. CrossRef
  66. Greiner J, Bullinger L, Guinn BA, Dohner H, Schmitt M: Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. / Clin Cancer Res 2008, 14:7161鈥?166. CrossRef
  67. Zhang Y, Shahriar M, Zhang J, Ahmed SU, Lim SH: Clofarabine induces hypomethylation of DNA and expression of Cancer-Testis antigens. / Leuk Res 2009, 33:1678鈥?683. CrossRef
  68. Heery DM, Hoare S, Hussain S, Parker MG, Sheppard H: Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. / J Biol Chem 2001, 276:6695鈥?702. CrossRef
  69. Coulthard VH, Matsuda S, Heery DM: An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220. / J Biol Chem 2003, 278:10942鈥?0951. CrossRef
  
• 作者单位：Frances Wadelin (1)
  Joel Fulton (1)
  Paul A McEwan (2)
  Keith A Spriggs (3)
  Jonas Emsley (2)
  David M Heery (1)
  
  1. Gene Regulation Group, Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK
  2. Protein Structure Group, Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK
  3. RNA Biology Group, Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK
  
• ISSN：1476-4598

文摘

PRAME/MAPE/OIP4 is a germinal tissue-specific gene that is also expressed at high levels in haematological malignancies and solid tumours. The physiological functions of PRAME in normal and tumour cells are unknown, although a role in the regulation of retinoic acid signalling has been proposed. Sequence homology and structural predictions suggest that PRAME is related to the leucine-rich repeat (LRR) family of proteins, which have diverse functions. Here we review the current knowledge of the structure/function of PRAME and its relevance in leukaemia.